AbbVie Inc. (ABBV)
NYSE: ABBV · IEX Real-Time Price · USD
185.16
+2.99 (1.64%)
At close: Jul 26, 2024, 4:00 PM
185.07
-0.09 (-0.05%)
After-hours: Jul 26, 2024, 7:58 PM EDT
AbbVie Employees
AbbVie had 50,000 employees as of January 31, 2024. The number of employees did not change compared to the previous year.
Employees
50,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,088,060
Profits / Employee
$119,860
Market Cap
326.97B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jan 31, 2024 | 50,000 | 0 | - |
Jan 31, 2023 | 50,000 | 0 | - |
Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
Jan 31, 2020 | 30,000 | 0 | - |
Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
Jan 31, 2013 | 21,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ABBV News
- 5 hours ago - AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations - Benzinga
- 18 hours ago - AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis - PRNewsWire
- 1 day ago - AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio - Investopedia
- 1 day ago - AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs - Benzinga
- 1 day ago - AbbVie Stock Is Rising on Strong Earnings. CEO Cites ‘Significant Momentum. - Barrons
- 1 day ago - AbbVie lifts annual profit forecast on strong immunology drug sales - Reuters
- 1 day ago - AbbVie's quarterly results top estimates as newer drugs cushion Humira's slide - Market Watch
- 1 day ago - AbbVie Reports Second-Quarter 2024 Financial Results - PRNewsWire